本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 关于公司 2025 年度权益分派预案的公告 股票代码：000999 股票简称：华润三九 公告编号：2026—006 华润三九医药股份有限公司 （一）权益分配预案的具体内容 根据《中华人民共和国公司法》和《公司章程》的有关规定，在兼顾公司发 展、长远利益、未来投资计划以及股东利益的前提下，公司拟定本年度权益分派 预案为：以未来实施分配方案时股权登记日的总股本为基数，向全体股东每 10 股派发现金红利 5.90 元（含税），送红股 0 股（含税），不以公积金转增股本。 特别提示： 1.公司 2025 年度权益分派预案为：以未来实施分配方案时股权登记日的总 股本为基数，向全体股东每 10 股派发现金红利 5.90 元（含税），送红股 0 股（含 税），不 以公 积金 转增 股本 。按 2025 年末 总股 本计 算， 共计 派发现 金 981,888,536.22 元（含税）。在实施权益分派的股权登记日前，如享有利润分配 权的股份总额发生变动，则以实施分配方案时股权登记日的享有利润分配权的股 份总额为基数，按照分配比例 ...

华润三九医药股份有限公司 2025 年年度报告全文 华润三九医药股份有限公司 2025 年年度报告全文 华润三九医药股份有限公司 2025 年年度报告全文 2026年是"十五五"规划的开局之年。站在新起点，公司将紧跟行业创新协同的发展浪 潮，心怀"国之大者"，深入推进"健康优先发展战略"落地生根，以新质生产力激活发展 动能，持续深化全产业链布局。 在创新研发上，聚焦关键领域，加大研发投入，加速成果转化，让更多高品质药品与健 康产品惠及大众；在智数化升级上，将"AI+"全面融入发展战略，夯实数据资产基石，拓 展新药研发、智慧供应链、智能生产、数字营销等场景应用，以技术赋能效率革新；在产业 协同上，深化与科研机构、医疗机构、零售伙伴的合作，共筑健康服务生态，践行"中医药 文化共链倡议"，推动中医药文化出海与产业升级；在自我革新上，进一步深化推进"敏捷 行动"；在社会责任上，坚守制药人的初心和使命，携手各利益相关方，以有温度、有实效 的履责实践守护大众健康。 华润三九医药股份有限公司 致股东一封信： 山不让尘，川不辞盈。五载春秋流转，我们步履不停，来到了承上启下的历史坐标上。 2025年，华润三九圆满收官"十四五" ...

Summary of Tianjin Tasly Pharmaceutical Conference Call Company Overview - **Company**: Tianjin Tasly Pharmaceutical Co., Ltd. - **Industry**: Pharmaceutical Strategic Goals - **2030 Strategic Target**: Achieve industrial revenue and profit of 15 billion RMB, doubling current figures and positioning among the top tier of Chinese pharmaceutical companies [2][5] - **Integration with China Resources Sanjiu**: Expected to enhance marketing, R&D, and management, with a 20% increase in terminal coverage by 2025 [2][3] Core Products and Market Expectations - **Compound Danshen Dripping Pills**: Sales expected to reach 300 million RMB by 2025, with the impact of price reductions from centralized procurement expected to diminish by 2026 [2][3] - **Puyouke for Stroke Indication**: Market potential expected to expand 4-5 times post-approval, with a target to develop it into a product exceeding 1 billion RMB in sales [2][3] - **Sales Growth of Core Products**: Five core products showed stable growth in 2025, with significant contributions from Qi Shen Yi Qi Dripping Pills and Yangxue Qingnao Granules, the latter exceeding 100 million RMB in sales [7][8] R&D and Innovation Focus - **R&D Transformation**: Shift from generic drug investment to focus on innovative traditional Chinese medicine (TCM) and advanced therapies, with 31 innovative drug candidates currently in development [2][5][12] - **Clinical Trials**: Multiple innovative TCM products are in Phase III clinical trials, showcasing strong competitive advantages in fever and gout treatment [2][5] Marketing and Sales Strategies - **"Fifteen" Strategic Plan**: A comprehensive plan focusing on innovation-driven growth, with nine key strategic initiatives including enhancing R&D efficiency, cost control, and marketing system improvements [3][5] - **Academic Promotion**: Emphasis on academic marketing to enhance product competitiveness and market share, particularly for core products [9][13] Financial Performance and Projections - **Revenue and Profit Growth**: Aiming for double-digit growth in revenue and profit by 2026 through a "foundation in hospitals, efficiency outside" business model [6][9] - **Sales and R&D Expenses**: Focus on cost control in sales expenses while increasing R&D investment in innovative drugs, reducing resources allocated to generics [22] Collaboration and Integration - **Synergy with China Resources Sanjiu**: Successful integration efforts have led to improved operational efficiency and enhanced market coverage, particularly in retail and e-commerce channels [6][10] - **Retail Strategy**: Plans to strengthen prescription management and patient education in the outpatient market, leveraging a large sales team for effective terminal activation [10][11] Emerging Therapeutic Areas - **Small Nucleic Acids and CGT**: Early-stage projects in small nucleic acids and cell and gene therapy (CGT) are being developed, with a focus on innovative treatment options [15][16] - **Market Potential for New Indications**: Significant market opportunities identified for new indications of existing products, particularly in stroke and metabolic diseases [17][18] Conclusion - **Overall Outlook**: The company is positioned for substantial growth through strategic integration, innovative product development, and enhanced marketing efforts, aiming to solidify its status as a leading player in the Chinese pharmaceutical market by 2030 [2][5][9]

Group 1: Industry Development and Strategic Positioning - The Chinese herbal medicine industry has seen a series of policies aimed at high-quality development, with a five-year plan (2026-2030) recently issued to guide the sector [2][3] - China’s aging population is projected to exceed 420 million by 2035, representing over 30% of the total population, indicating a significant shift in health demands [11] - The company aims to transform from a single business focus to three distinct areas: consumer health, medical health, and silver health, with each area led by a different listed company [15] Group 2: Innovation and Product Development - The company has established a systematic innovation product development model, focusing on self-research, external collaborations, and strategic acquisitions [4][5] - There are currently 31 innovative drugs in the pipeline, with some already submitted for new drug applications, indicating a robust R&D strategy [8] - The company plans to enhance its product pipeline through a dual approach of internal innovation and external partnerships, aiming to maintain a competitive edge in the market [6][7] Group 3: Market Trends and Challenges - The retail market is evolving with increasing specialization, a rising proportion of prescription drugs, and a trend towards non-medical products such as cosmetics and health supplements [14][15] - The industry faces challenges from policy-driven cost controls and the need to adapt to a non-insurance market environment, which has led to a wave of store closures [14] - The company is exploring new consumer demands driven by aging and emotional consumption trends, while also leveraging technology such as AI to enhance operational efficiency [15] Group 4: Collaborative Synergies and Future Outlook - The integration of Kunming Pharmaceutical Group into the company is expected to enhance strategic focus and resource sharing, particularly in the silver health sector [13] - The company is committed to optimizing its operational management and brand-building capabilities to strengthen its market position [13] - Future strategies will emphasize capturing opportunities in the evolving market landscape while ensuring sustainable long-term value for investors [15]

Investment Rating - The report does not explicitly provide an investment rating for the industry Core Insights - The goji berry health food market is expected to grow significantly due to increasing health awareness, an aging population, and innovation in product development [4][9] - The market size is projected to increase from 17.247 billion RMB in 2020 to 19.620 billion RMB in 2024, with a compound annual growth rate (CAGR) of 3.27%, and further to 23.955 billion RMB by 2029, with a CAGR of 4.26% [8] - The industry is transitioning from traditional nourishment to precise health solutions, focusing on scientific validation and functional differentiation [29] - The supply chain is evolving from traditional cultivation to a comprehensive industry chain, enhancing quality and sustainability [30] - Consumer demand is diversifying, with a shift from single goji berry products to a variety of health-focused applications [11][12] Market Background - Goji berry health foods are primarily made from goji berries, known for their health benefits such as lowering blood pressure and enhancing immunity [4][5] - The market has evolved through distinct phases, starting from its inception in the late 1990s to a rapid growth phase expected to continue until 2025 [6][7] Market Status - The market is experiencing a significant transformation in supply and demand dynamics, with a shift towards integrated supply chains and diverse product offerings [10] - The demand for goji berry health foods is increasing as consumers seek natural and effective health management options [11] Market Competition - The industry is characterized by severe product homogeneity, with leading companies including China Resources Sanjiu, Tongrentang, and Harbin Pharmaceutical Group [16][17] - The report identifies ten recommended brands based on economic returns, profitability, and industry depth [13][14][15] Development Trends - The industry is moving towards high-quality development across the entire supply chain, ensuring product quality and value enhancement [30] - Consumption scenarios for goji berry health foods are expanding beyond traditional uses to include modern lifestyle applications [31]

Group 1 - In March 2025, China Resources Sanjiu acquired control of Tianshili for 5.99 billion yuan, resulting in an additional goodwill of 1.921 billion yuan [1][14] - The acquisition is part of a significant asset restructuring, with China Resources Sanjiu focusing on expanding its innovative traditional Chinese medicine business [14][15] - Tianshili's revenue for the first half of 2025 was 2.054 billion yuan, accounting for 13.87% of China Resources Sanjiu's consolidated revenue [15] Group 2 - Tianshili reported a total revenue of 8.236 billion yuan and a non-recurring net profit of 787 million yuan for 2025, reflecting a year-on-year decline of 3.08% and 24.06% respectively [16] - The decline in Tianshili's revenue is primarily attributed to a 14.24% decrease in pharmaceutical commercial income, mainly from chain pharmacy operations [16] - China Resources Sanjiu's revenue for 2025 was 31.629 billion yuan, with a year-on-year increase of 14.53% [16] Group 3 - The Tianjin Securities Regulatory Bureau issued four administrative penalties related to insider trading connected to the acquisition, indicating potential misuse of sensitive information [3][11] - The penalties involved individuals who traded stocks based on insider information during the sensitive period, with total illegal gains and fines imposed [12][13] - The stock of Tianshili saw a significant increase in trading volume and price following the announcement of the acquisition, with a single-day price increase of 6.18% on July 31, 2024 [13]

Sector Insights - The current booming sectors for 2025 earnings forecasts are primarily in new energy, pharmaceuticals, and technology[12] - Key stocks in the energy metals sector include Huayou Cobalt, which reported significant increases in product prices and production volumes[1] - In the battery sector, companies like Putailai and Xianhui Technology are highlighted due to rapid growth in demand from the new energy vehicle and energy storage markets[1] - The pharmaceutical sector shows a divergence in performance, with WuXi AppTec indicating stable growth while Dian Diagnostics faces revenue pressure[2] Market Performance - A-shares experienced slight gains with a focus on technology stocks driven by AI industry catalysts, while consumer sectors lagged[3] - The A-share ERP is currently at 2.52%, reflecting a slight recovery in market risk appetite[3] - Global equity markets mostly rose, with Asian markets leading; the KOSPI, Taiwan Stock Exchange, and Nikkei 225 saw increases of 8.21%, 5.74%, and 4.96% respectively[6] Policy and Economic Indicators - January's macroeconomic indicators in China showed positive signals, with core CPI improving and PPI's decline narrowing[7] - The U.S. labor market added 130,000 jobs in January, exceeding expectations, while CPI data met forecasts, indicating a stable inflation environment[7]

Core Viewpoint - The Medical Health R Index (480016) closed at 7183.97 points on February 9, with a slight increase of 0.31% and a trading volume of 23.45 billion yuan, indicating a stable performance in the healthcare sector [1]. Group 1: Index Performance - The Medical Health R Index recorded a trading volume of 23.45 billion yuan and a turnover rate of 1.01% on the reporting day [1]. - Among the constituent stocks, 31 companies experienced an increase, with China Resources Sanjiu leading with a rise of 4.48%, while 18 companies saw a decline, with Baillie Tianheng leading the drop at 3.43% [1]. Group 2: Capital Flow - The net outflow of main funds from the Medical Health R Index constituent stocks totaled 353 million yuan, while retail investors contributed a net inflow of 306 million yuan [2]. - The net inflow from speculative funds amounted to 47.65 million yuan, indicating varied investor interest across different segments [2].

Core Insights - The company reported a total operating revenue of 31.629 billion yuan for the year 2025, representing a year-on-year growth of 14.53% [1] - The net profit attributable to shareholders of the listed company reached 3.422 billion yuan, with a year-on-year increase of 1.60% [1] Strategic Focus - The company aims to adhere to a dual-driven strategy of "innovation + brand" to navigate a complex market environment [1] - The focus is on core treatment areas, expanding the research and development pipeline from multiple dimensions to uncover innovative value [1] - The company is committed to enhancing brand advantages, optimizing business layout, and forging a competitive edge across the entire industry chain to solidify its leading position in the industry [1] - The strategic goal is to strive to become a top enterprise in the industry [1]

Investment Rating - The report maintains a "Buy" rating for key companies in the pharmaceutical sector, including Innovent Biologics, Efang Biologics, Tianshili, WuXi AppTec, and Mindray Medical [4][28]. Core Insights - The policy-driven upgrade of traditional Chinese medicine (TCM) industry is expected to enhance industry concentration in the medium to long term, benefiting companies with strong quality control and innovative capabilities [2][24]. - The implementation plan for high-quality development of the TCM industry aims to establish a collaborative development system by 2030, focusing on raw material supply, innovation, production quality control, and internationalization [2][23]. - The investment strategy emphasizes the importance of clinical value in the pharmaceutical sector, recommending a focus on innovative drugs and high-end medical devices [3][26]. Summary by Sections Market Review - The A-share pharmaceutical index rose by 0.14%, outperforming the CSI 300 index by 1.47 percentage points [1][16]. - The Hong Kong Hang Seng Medical Health Index fell by 1.41%, but still outperformed the Hang Seng Index by 1.65 percentage points [1][16]. Policy Insights - The Ministry of Industry and Information Technology and other departments issued a plan to enhance the TCM industry, which includes fostering leading enterprises and establishing high-standard raw material production bases [2][24]. - The plan emphasizes digitalization and sustainability, aiming to raise compliance standards and accelerate the exit of smaller companies from the market [2][25]. Company Updates - Recent clinical progress includes the NDA submission for HRS-9531 by Heng Rui Medicine and the initiation of clinical trials for various drugs by other companies [1][31][32]. - Key companies such as Yunnan Baiyao, Baiyunshan, and Taiji Group are highlighted for their strong positions in raw material supply [2][25]. Financial Forecasts - The report provides earnings per share (EPS) forecasts for key companies, with Innovent Biologics projected to have an EPS of 0.49 in 2025 and WuXi AppTec expected to reach an EPS of 5.07 in the same year [4][28]. - The pharmaceutical manufacturing industry reported a revenue decline of 1.2% year-on-year for 2025, with total revenue reaching 2,487 billion yuan [51].